BioCentury
ARTICLE | Clinical News

Ertugliflozin: Phase III started

February 3, 2014 8:00 AM UTC

Pfizer disclosed in its 4Q13 earnings that it began a double-blind, placebo-controlled, U.S. Phase III trial to compare 5 and 15 mg oral ertugliflozin once daily plus metformin for 2 years vs. glimepi...